Capsugel injects molding tech into oral forms

Pfizer's Capsugel unit has garnered rights to the FlexTab dosage-form platform, following eight years of effort with drug giant GSK. FlexTab extends Capsugel's base of oral-delivery formulation technology beyond dip-molding to injection-molding processes.

FlexTab accommodates  various fill materials, including powders, pellets, liquids, micro-tablets and tablets. The company says the technology also can deliver separate liquid and powder APIs in one dose.

Separately, UK contract manufacturer Molecular Profiles is adding a Capsugel Xcelodose 1205 powder micro-doser for capsule and vial filling. The CMO sees the unit, which provides for dosing in quantities as small as 100 micrograms, as a way to attract business from sponsors running early-phase studies. Precision small-quantity dosing lets sponsors skip formulation development and stability studies, the company says.

- see the Molecular Profiles release
- here's the FlexTab announcement

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.